Home Investors Financial Information Sales of Major Products Sales of Major Products Important Notice This website contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, or in different dosages. Nothing contained herein should be considered a solicitation, promotion or advertisement for any drug including the ones under development on this web site. Any information on the products contained herein is not intended to provide medical advice nor should be used as a substitute for the advice provided by your physician or other healthcare provider. I Agree INVESTORS Corporate Strategic Plan 2021 Financial Information Financial Highlights Financial Data (Annual Data) Financial Data (Quarterly Data) Sales of Major Products Revenue by Region Annual Report IR Library IR Calendar Stock & Rating Information Analyst Coverage Cautionary Statement Bottom footer menu SITE MAP PRIVACY POLICY ACCESSIBILITY TERMS OF USE CONTACT US DISASTER INFORMATION FOR EMPLOYEES © Astellas Pharma Inc.

Home Investors Stock & Rating Information Current Share Status Current Share Status Important Notice This website contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, or in different dosages. Nothing contained herein should be considered a solicitation, promotion or advertisement for any drug including the ones under development on this web site. Any information on the products contained herein is not intended to provide medical advice nor should be used as a substitute for the advice provided by your physician or other healthcare provider. I Agree (as of September 30, 2021) Number of shareholders: 92,035 Common stock Authorized: 9,000,000,000 Common stock Issued: 1,861,787,075 Breakdown of Shareholders by Type Top ten (10) principal shareholders in the register of shareholders: Name of shareholders Number of shares held (Thousand) Percentage of shares held (%) 1 The Master Trust Bank of Japan, Ltd. (trust account) 334,562 17.97 2 Custody Bank of Japan, Ltd. (trust account) 132,547 7.12 3 STATE STREET BANK AND TRUST COMPANY 505001 71,756 3.85 4 Nippon Life Insurance Company 53,036 2.85 5 Custody Bank of Japan, Ltd. (trust account 7) 44,307 2.38 6 STATE STREET BANK WEST CLIENT - TREATY 505234 32,229 1.73 7 JP MORGAN CHASE BANK 385781 25,301 1.35 8 SSBTC CLIENT OMNIBUS ACCOUNT 24,014 1.29 9 Custody Bank of Japan, Ltd. (securities investment trust account) 19,563 1.05 10 STATE STREET BANK AND TRUST COMPANY 505103 19,008 1.02 ※ Number of shares held are presented by discarding the numbers down to the thousand, and percentage of shares are presented by discarding the numbers down to the third decimal. INVESTORS Corporate Strategic Plan 2021 Financial Information Annual Report IR Library IR Calendar Stock & Rating Information Shareholders Meeting Shareholder Return Current Share Status Chart Issuer Rating Analyst Coverage Cautionary Statement Bottom footer menu SITE MAP PRIVACY POLICY ACCESSIBILITY TERMS OF USE CONTACT US DISASTER INFORMATION FOR EMPLOYEES © Astellas Pharma Inc.